Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer (Review)

Telang,Nitin

doi:10.3892/br.2017.958

Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer (Review)

Authors:
- Nitin Telang
View Affiliations

Affiliations: Cancer Prevention Research Program, Palindrome Liaisons Consultants, Montvale, NJ 07645‑1559, USA
Published online on: August 1, 2017 https://doi.org/10.3892/br.2017.958
Pages: 199-204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Global gene expression profiling identifies predictive and prognostic biomarkers and rationalizes breast cancer subtype-targeted treatment. The Anthracyclin/Taxol and survival pathway specific small molecular inhibitors, constitute current treatment options. These options are associated with acquired tumor resistance and emergence of drug-resistant cancer stem cells. Dietary supplements and constitutive bioactive phytochemicals with relatively low systemic toxicity may provide testable alternatives for current therapy. Human breast epithelial cell lines 184‑B5 (non‑tumorigenic triple negative cell type) and MDA‑MB‑231 (breast carcinoma derived triple negative cell type) were used as the experimental models. Putative cancer chemo‑preventive natural products and their constitutive bioactive agents represented the test agents. Anchorage independent growth, cell cycle progression and cell apoptosis quantified the treatment efficacy. Compared to the 184‑B5 cells, the MDA‑MB‑231 cells exhibited anchorage-independent growth indicative of persistent cancer risk. Additionally, the MDA‑MB‑231 cells exhibited hyper‑proliferation, accelerated cell cycle progression and inhibited apoptosis indicative of loss of homeostatic growth control. The test agents inhibited anchorage-independent growth via cytostatic and pro‑apoptotic effects. The triple negative carcinoma-derived Doxorubicin-resistant phenotype exhibited cancer stem cell markers, including tumor spheroid formation and expression of CD44, NANOG and c‑Myc. These data identify clinically relevant mechanistic leads for the efficacy of natural products in the aggressive therapy‑resistant breast cancer subtype and suggests a testable approach for cancer stem cell-targeted therapy.

View Figures

View References

1	American Cancer Society - Facts and Figures. American Cancer Society. Atlanta: 2016.
2	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M and Jeffrey SS: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
3	Baselga J and Swain SM: Novel anti-cancer agents: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
4	Dinh P, Satirou C and Piccart MJ: The evaluation of treatment strategies: Aiming at the target. 16:S10–S16. 2007.
5	Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW and Carey LA: Poly (ADP-ribose) inhibition: Targeted therapy for triple negative breast cancer. Clin Cancer Res. 16:4702–4710. 2010. View Article : Google Scholar : PubMed/NCBI
6	Dean M, Fojo T and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar : PubMed/NCBI
7	Tindle HA, Davis RB, Phillips RL and Eisenburg DM: Trends in the use of complementary and alternative medicines by US adults: 1997-2002. Altern Ther Health Med. 11:42–49. 2005.PubMed/NCBI
8	Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S, Bruyns I, Fernadez-Ortega P, Panteli V, Margulies A and Gudmundsdottir G: Complementary and alternative medicine use in breast cancer patient in Europe. Support Care Cancer. 14:206–267. 2006. View Article : Google Scholar
9	Helyer LK, Chin S, Chui BK, Fitzgerald B, Verma S, Rakovitch E, Dranitsaris G and Clemons M: The use of complementary and alternative medicine among patients with locally advanced breast cancer. A descriptive study. BMC Cancer. 6:39–46. 2006. View Article : Google Scholar : PubMed/NCBI
10	Mukherjee B, Telang N and Wong GYC: Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellandae tree. Int J Mol Med. 24:253–260. 2009.PubMed/NCBI
11	Li G, Sepkovic DW, Bradlow HL, Telang NT and Wong GYC: Lycium barbarum inhibits growth of estrogen receptor positive human breast cancer cells by favorably altering estradiol metabolism. Nutr Cancer. 61:408–414. 2009. View Article : Google Scholar : PubMed/NCBI
12	Telang NT, Li G, Sepkovic DW, Bradlow HL and Wong GYC: Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor positive clinical breast cancer. Mol Med Rep. 5:22–28. 2012.PubMed/NCBI
13	Telang N, Li G, Sepkovic D, Bradlow HL and Wong GYC: Comparative efficacy of extracts form Lycium barbarum bark and fruit on estrogen receptor positive human mammary carcinoma MCF-7 cells. Nutr Cancer. 66:278–284. 2014. View Article : Google Scholar : PubMed/NCBI
14	Telang N, Li G, Katdare M, Sepkovic D, Bradlow L and Wong GYC: Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function. Oncol Lett. 12:3949–3957. 2016.PubMed/NCBI
15	Telang NT, Li G, Katdare M, Sepkovic DW, Bradlow HL and Wong GYC: The nutritional herb Epimedium grandiflorum inhibits the growth in a model for the Luminal A molecular subtype of breast cancer. Oncol Lett. 13:2477–2482. 2017.PubMed/NCBI
16	Katdare M, Osborne MP and Telang NT: Novel cell culture models for prevention of human breast cancer. Int J Oncol. 22:505–519. 2003.(Review).
17	Katdare M, Osborne MP and Telang NT: Soy isoflavone genestein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells. Int J Oncol. 21:809–816. 2002.PubMed/NCBI
18	Telang N and Katdare M: Epithelial cell culture models for prevention and therapy of clinical breast cancer (Review). Oncol Lett. 3:744–750. 2012.PubMed/NCBI
19	Telang NT, Nair HB and Wong GYC: Efficacy of Tabebuia avellandae extract on a cell culture model for triple negative breast cancer. Cancer Res. 74:(Suppl.): SABCS Abstract no. P5-14-02. 2014.
20	Telang NT, Nair HB and Wong GYC: Effect of Cornus officinalis (CO) on a model for triple negative breast cancer. Cancer Res. 75:(Suppl.): SABCS Abstract no. P3-09-04. 2015.
21	Telang N, Nair HB and Wong GYC: Efficacy of Dipsacus asperoides (DA) in a model for triple negative breast cancer. Cancer Res. 76:(Suppl.): SABCS Abstract no. P4-13-04. 2016.
22	Stampfer MR and Bartley JC: Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to Benzo (α) pyrene. Proc Natl Acad Sci USA. 82:2394–2398. 1985. View Article : Google Scholar : PubMed/NCBI
23	Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F and Speed T: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527. 2006. View Article : Google Scholar : PubMed/NCBI
24	Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P, Xing L, Hung MC, Bonfiglio T, Hicks DG and Tang P: Expression patterns of ER, PR, HER-2, CK5/6, Ki67 and AR by immuno-histochemical analysis in breast cancer cell lines. Breast Cancer. 4:35–41. 2010.PubMed/NCBI
25	Hudis CA and Gianni L: Triple negative breast cancer: An unmet medical need. Oncologist. 16:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
26	Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP and Weeks JC: Clinicopathological features, patterns of recurrence and survival amongst women with triple negative breast cancer in National Comprehensive Cancer Network. Cancer. 118:5463–5472. 2012. View Article : Google Scholar : PubMed/NCBI
27	Gorsky DH: Integrative oncology: Really the best of both worlds? Nat Rev Cancer. 14:692–700. 2014.
28	Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, Ma W, Georgiadis C, Laskin JD and Conney AH: Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res. 54:701–708. 1994.PubMed/NCBI
29	Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AD: Resveratrol inhibits Cyclo-oxygenase transcription and activity in phorbol ester treated human mammary epithelial cells. J Biol Chem. 273:21875–21882. 1998. View Article : Google Scholar : PubMed/NCBI
30	Subbaramaiah K, Michaluart P, Sporn MB and Dannenberg AJ: Ursolic acid inhibits cyclo-oxygenase-2 transcription in human mammary epithelial cells. Cancer Res. 60:2399–2404. 2000.PubMed/NCBI
31	Subbaramaiah K, Cole PA and Dannenberg AJ: Retinoids and carnasol suppress cyclo-oxygenase-2 transcription by CREB binding protein/p300-dependent and independent mechanisms. Cancer Res. 62:2522–2530. 2002.PubMed/NCBI
32	Cox LA, Chen G and Lee EY: Tumor suppressor genes and their role in breast cancer. Breast Cancer Res Treat. 32:19–38. 1994. View Article : Google Scholar : PubMed/NCBI
33	Burkhart DL and Sage J: Cellular mechanisms of tumor suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI
34	Bosco EE and Knudson ES: RB in breast cancer: At the crossroads of tumorigenesis and treatment. Cell Cycle. 6:667–671. 2007. View Article : Google Scholar : PubMed/NCBI
35	Van Arsdale T, Boschoff C, Arndt KT and Abraham RT: Molecular pathways: Targeting the Cyclin D-CDK 4/6 axis for cancer treatment. Clin Cancer Res. 21:2905–2910. 2015. View Article : Google Scholar : PubMed/NCBI
36	Muller PAJ and Vousden KH: Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. 25:304–317. 2014. View Article : Google Scholar : PubMed/NCBI
37	Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji J, Mason MD and Jiang WG: Traditional Chinese medicine in the prevention and treatment of breast cancer and cancer metastasis. Oncol Lett. 10:1240–1250. 2015.PubMed/NCBI
38	Stingl J and Caldas C: Molecular heterogeneity of breast carcinoma and the cancer stem cell hypothesis. Nat Rev Cancer. 7:791–799. 2007. View Article : Google Scholar : PubMed/NCBI
39	Lobo NA, Shimono Y, Quan D and Clarke MF: The biology of cancer stem cells. Annu Rev Cell Dev Biol. 23:675–699. 2007. View Article : Google Scholar : PubMed/NCBI
40	Patel SA, Ndabahaliye A, Lim PK, Milton R and Rameshwar P: Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer. 2:1–11. 2010.PubMed/NCBI
41	Telang N: Putative cancer initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer. Oncol Lett. 10:3840–3846. 2015.PubMed/NCBI
42	Telang N: Anti-inflammatory drug resistance selects putative cancer stem cells in a cellular model for genetically predisposed colon cancer. Oncol Lett (In press).
43	Zhang F, Song C, Ma Y, Tang L, Xu Y and Wang H: Effect of fibroblasts on breast cancer cell mammosphere formation and regulation of stem cell related gene expression. Int J Mol Med. 28:365–371. 2011.PubMed/NCBI
44	Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131:861–872. 2007. View Article : Google Scholar : PubMed/NCBI
45	Park IH, Zhao R, West JA, Yabuuci A, Huo H, Ince TA, Lerou PH, Lansch MW and Daley GQ: Reprograming of human somatic cells to pluripotency with defined factors. Nature. 451:141–146. 2008. View Article : Google Scholar : PubMed/NCBI
46	Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II and Thomson JA: Human induced pluripotent stem cells free of vector and transgene sequences. Science. 324:797–800. 2009. View Article : Google Scholar : PubMed/NCBI
47	Ishida R, Koyanagi-Aoi M, Oshima N, Kakeji Y and Aoi T: The tissue reconstructing ability of colon CSCs is enhanced by FK506 and suppressed by GSK3 inhibition. Mol Cancer Res. July 14–2017.(Epub ahead of print). https://doi.org/10.1158/1541-7786.MCR-17-0071 View Article : Google Scholar